Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia

Iopofosine I 131 in Waldenström macroglobulinemia: CLOVER-WaM HighlightsPatients in the per-protocol population achieved an MRR of 61.8% in addition to an ORR of 83.6% and a median DoR of 17.8 months.The MRRs for patients who had previously been exposed to BTK inhibitors or were refractory to BTK inhibitors were 64.1% and 63.6%, respectively.Iopofosine I 131 demonstrated a manageable and predictable safety profile.